Qtrex Quantum Ltd. is a US-listed company in the health care equipment industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: every model's value for Qtrex Quantum Ltd. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Price vs value
Under review: cash-flow, stock-pay or share-count figures missing or out of date. We'll show the comparison once resolved.
Qtrex Quantum Ltd. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders2 buying, 2 selling4 purchases and 7 sales by directors and officers, last 12 monthsInsider trades
- Funds18 adding, 4 cuttingOf 2 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Where it lags: stock pay as % of revenue of 1237.0% ranks 119 of 123 health care equipment companies we cover.
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 4.5% while net income fell 19.6%: a 15pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Net cash. Cash exceeds long-term debt by $0.0bn.
Things to watch
- Loss-making. Operating margin is -4713.8%: costs exceed revenue.
- Burning cash. Free cash flow was -3447.8% of revenue over the last 12 months.
- Heavy stock-based pay. Stock pay equals 1237.0% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
- Share dilution. Diluted shares rose 60.0% in a year.
- Volatile shares. Over the past year the shares showed annualised volatility of 233% and a beta of 4.6 against the S&P 500.
- Below peers: gross margin. Gross margin of 0.7% ranks 118 of 123 health care equipment companies we cover (median 61.9%).
Price chart
- 1 day-8.2%
- 1 week-13.2%
- 1 month+1.8%
- This year+24.4%
- 1 year+20.4%
- 5 years-69.8%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- Revenue (TTM)
- $289,000
- Operating margin
- -4713.8%
- Net margin
- -4574.4%
- EPS (TTM, diluted)
- $-0.45
Growth
- Share count change
- +60.0%
Cash
- Free cash flow (TTM)
- -$10M
- FCF margin
- -3447.8%
- Stock pay % of revenue
- 1237.0%
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for QTEX from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
Valuation models
We value Qtrex Quantum Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 12.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.67 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$0.0 ~$0.0–$0.0 | Left out: out of range vs price (0.01x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Qtrex Quantum Ltd. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Valuation multiples over time Market data may be delayed
| At fiscal year end | 2023 | 2024 | 2025 |
|---|---|---|---|
| Share price | $1.06 | $1.02 | $0.90 |
| Market value | $13m | $19m | $27m |
| + Net debt (− = net cash) | −$5m | −$5m | −$3m |
| Enterprise value | $8m | $14m | $24m |
| Multiples | |||
| Price / sales | — | — | 92.3x |
| Price / earnings | — | — | — |
| Price / free cash flow | — | — | — |
| EV / EBITDA | — | — | — |
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | $0.10 | +122% | $48m | +16509% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −9.1% on 90 days ago. In the last 30 days, 1 analyst raised Qtrex Quantum Ltd.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year |
|---|---|
| 90 days ago | $0.11 |
| 60 days ago | $0.11 |
| 30 days ago | $0.11 |
| 7 days ago | $0.11 |
| Now | $0.10 |
Positioning
- Short interest
- 6.6% of tradable shares
- Days to cover
- 0.21 at average volume
- Short interest, 1 month
- +14% to October 15, 2026
- Held by institutions
- 11% of shares
- Held by insiders
- 13.7% of shares
- Employees
- 34 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|
| Return | |||||
| QTEX | −69% | −18% | −4% | −12% | +24% |
| Industry peers (median) | −37% | −8% | −20% | −16% | −15% |
| S&P 500 | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | |||||
| QTEX | 33% | 33% | 50% | 50% | 18% |
| S&P 500 | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | |||||
| QTEX | −76% | −51% | −62% | −61% | −78% |
| S&P 500 | −25% | −10% | −8% | −19% | −9% |
Worst fall since July 14, 2021: 97% from October 26, 2021 to May 21, 2026. Getting back needed a 3065% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.30 – $3.08
- From 52-week high
- −63.6%
- vs 50-day average
- +2.2%
- vs 200-day average
- +15.3%
- Volatility (1 year)
- 233%
- Beta vs S&P 500
- 4.58
Fundamentals
Financial statements
| Fiscal year | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|
| Income | |||
| Revenue | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 |
| EBITDA | −12 | −11 | −13 |
| Operating income | −12 | −11 | −14 |
| Net income | −11 | −11 | −13 |
| Diluted EPS | −$0.93 | −$0.60 | −$0.45 |
| Margins | |||
| Gross margin | — | — | 0.7% |
| EBITDA margin | — | — | <−999% |
| Operating margin | — | — | <−999% |
| Net margin | — | — | <−999% |
| Free-cash-flow margin | — | — | <−999% |
| Cash flow | |||
| Cash from operations | −10 | −9 | −10 |
| Capital spending | 0 | 0 | 0 |
| Free cash flow | −10 | −10 | −10 |
| Stock-based pay | 1 | 2 | 4 |
| Free cash flow after stock pay | −11 | −11 | −14 |
| Balance sheet | |||
| Cash | 5 | 5 | 3 |
| Total debt | 0 | 0 | 0 |
| Net debt (negative = net cash) | −5 | −5 | −3 |
| Diluted shares | 12m | 19m | 30m |
Financial health
- Short-term assets cover short-term liabilities $4m of assets due within a year against $3m of liabilities due within a year.
- Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +60.0%
- year over year
- R&D spending
- 2593.8%
- of revenue
Competitors: side by side with peers
| Last 12 months unless stated | QTEX | NXL | ITOC | CODX | PAVM | POAS | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $289000 | $217155 | $523031 | $721387 | $112000 | $102806 | $99m |
| Revenue growth, last 12 months | — | 24.2% | 16.7% | −28.1% | −89.0% | −18.2% | 9.2% |
| Revenue growth, 3-year average | — | −30.6% | — | −53.8% | −49.6% | — | 13.5% |
| Revenue growth, latest quarter | — | −82.8% | — | 2.0% | 450.0% | — | 10.2% |
| Gross margin | 0.7% | 86.2% | 62.6% | 43.5% | −220.5% | 13.1% | 61.2% |
| Operating margin | <−999% | <−999% | −991.7% | <−999% | <−999% | <−999% | −8.5% |
| Operating margin, 3-year average | — | <−999% | — | <−999% | <−999% | — | −17.9% |
| Net margin | <−999% | <−999% | −974.7% | <−999% | <−999% | <−999% | −12.0% |
| Cash from operations / revenue | <−999% | <−999% | −617.8% | <−999% | <−999% | <−999% | −1.9% |
| Free-cash-flow margin | <−999% | <−999% | −618.6% | <−999% | <−999% | <−999% | −3.9% |
| Free-cash-flow margin, 3-year average | — | <−999% | — | <−999% | <−999% | — | −7.0% |
| Stock pay / revenue | >999% | >999% | 563.2% | 169.9% | >999% | — | 6.1% |
| Change in share count | 60.0% | 52.1% | 26.1% | 4.0% | 14.0% | 19.7% | 4.0% |
Peer comparison
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Gross margin Profitability | 0.7% | 61.9% | 118 of 123 |
| Operating margin Profitability | -4713.8% | -8.3% | 127 of 132 |
| Net margin Profitability | -4574.4% | -12.0% | 127 of 133 |
| Free-cash-flow margin Cash generation | -3447.8% | -3.4% | 123 of 128 |
| Stock pay as % of revenue Cash generation | 1237.0% | 6.1% | 119 of 123 |
| Change in share count Balance sheet | 60.0% | 3.3% | 108 of 115 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
Who owns it
Funds buying and selling- Reported value
- $3.9M
- Institutions reporting
- 28
- Shares held vs prior quarter
- ▼ 57.9%
- Positions opened / closed
- 13 / 3
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Citadel Advisors LLC | $2M | 1.4M | 52.6% | New |
| Caitong International Asset Management Co., Ltd | $358,648 | 249K | 9.2% | New |
| Foundations Investment Advisors, LLC | $285,120 | 198K | 7.4% | New |
| Slt Holdings LLC | $285,120 | 198K | 7.4% | New |
| Jane Street Group, LLC | $204,382 | 142K | 5.3% | ▲ 608.0% |
| Virtu Financial LLC | $154,000 | 107K | 4.0% | New |
| Kestra Advisory Services, LLC | $113,507 | 79K | 2.9% | 0.0% |
| Susquehanna International Group, LLP | $76,971 | 53K | 2.0% | ▼ 10.5% |
| Xtx Topco Ltd | $72,973 | 51K | 1.9% | ▲ 0.9% |
| LPL Financial LLC | $62,208 | 43K | 1.6% | New |
| Invesco Ltd. | $49,365 | 34K | 1.3% | New |
| UBS Group AG | $34,778 | 24K | 0.9% | ▲ 65.3% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Qtrex Quantum Ltd.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Parnes Tal Director | October 15, 2026 | Buy | 6,666 | $1.50 | $9,999 |
| Ben-Noon Dagi Shahar Chief Executive Officer | October 13, 2026 | Buy | 14,093 | $1.49 | $20,999 |
| Ben-Noon Dagi Shahar Chief Executive Officer | October 9, 2026 | Buy | 18,181 | $1.67 | $30,362 |
| Ben-Noon Dagi Shahar Chief Executive Officer | September 28, 2026 | Buy | 168,894 | $0.71 | $119,915 |
| Tehila Yafit Chief Financial Officer | June 1, 2026 | Sell pre-set plan | 28,100 | $3.50 | $98,350 |
| Tehila Yafit Chief Financial Officer | May 29, 2026 | Sell pre-set plan | 1,900 | $3.51 | $6,669 |
| Yechezkely Hayon Daniella Chief Technology Officer | May 29, 2026 | Sell | 50,000 | $3.00 | $150,000 |
| Tehila Yafit Chief Financial Officer | May 28, 2026 | Sell pre-set plan | 15,000 | $2.56 | $38,400 |
| Tehila Yafit Chief Financial Officer | May 28, 2026 | Sell pre-set plan | 15,000 | $3.00 | $45,000 |
| Tehila Yafit Chief Financial Officer | May 27, 2026 | Sell pre-set plan | 13,605 | $2.03 | $27,618 |
| Tehila Yafit Chief Financial Officer | May 27, 2026 | Sell pre-set plan | 16,395 | $2.01 | $32,954 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Qtrex Quantum Ltd. in brief
- What does Qtrex Quantum Ltd. do?
- Qtrex Quantum Ltd. is a US-listed company in the health care equipment industry. Its financial year ends in December.
- What is Qtrex Quantum Ltd.'s stock ticker?
- Qtrex Quantum Ltd. trades under the ticker QTEX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- What is Qtrex Quantum Ltd.'s free cash flow?
- Qtrex Quantum Ltd.'s free-cash-flow margin is -3447.8% of revenue over the trailing twelve months, ranking 123 of the 128 health care equipment companies we cover.
- Who are Qtrex Quantum Ltd.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Citadel Advisors LLC, Caitong International Asset Management Co., Ltd and Foundations Investment Advisors, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- What is Qtrex Quantum Ltd.'s market cap?
- On December 31, 2025, Qtrex Quantum Ltd.'s market capitalisation was about $26.7M and net debt of -$3.2M. Market figures come from third-party market data and may be delayed.
- Who are Qtrex Quantum Ltd.'s competitors?
- In our Health Care Equipment peer group, the companies closest to Qtrex Quantum Ltd. are Nexalin Technology, Inc., Itonic Holdings Ltd, Co-diagnostics, Inc., Pavmed Inc. and Phaos Technology Holdings (cayman) Ltd. The side-by-side comparison below sets their revenue, margins and growth against Qtrex Quantum Ltd.'s.
- Are insiders buying or selling Qtrex Quantum Ltd. stock?
- Over the last 12 months, Qtrex Quantum Ltd.'s directors and officers reported 4 open-market purchases and 7 sales on Form 4. The insider trading page charts every trade.
Follow research on Qtrex Quantum Ltd.
New research on the companies we cover arrives in the weekly email. Free, one email a week.